❌

Normal view

ASML vs. SK Hynix: What Revenue Trends Reveal to Investors About These Artificial Intelligence Companies

Key Points

  • SK Hynix currently generates a higher overall revenue total at the end of each period than ASML Holding.

  • Throughout the course of the last eight quarters, ASML maintained steady quarter-over-quarter revenue totals, while SK Hynix demonstrated a distinct quarter-over-quarter acceleration in its reported results.

  • As these financial patterns continue to develop, investors should watch whether the existing revenue gap between the two companies continues to widen or begins to narrow in upcoming quarters.

ASML Holding: Steady and Gradual Quarterly Revenue Growth

ASML Holding (NASDAQ:ASML) generates its revenue primarily by supplying advanced extreme ultraviolet lithography equipment, specialized wafer inspection systems, and related computational control software to integrated circuit manufacturers operating in locations across the globe.

It recently announced plans to increase manufacturing capacity for specific immersion systems by 30%, launched a collaborative industry initiative with multiple foundries for larger photomasks, and initiated construction on an additional corporate engineering campus in the Netherlands.

SK Hynix: Rapid and Sustained Quarterly Revenue Expansion

SK Hynix (NASDAQ:SKHY) earns its revenue primarily by designing, producing, and selling a wide variety of advanced memory semiconductors, including various customized flash memory products tailored specifically for complex technical computing and mobile applications.

It recently completed an oversubscribed initial listing of its American Depositary Receipts on the Nasdaq exchange, reassigned three senior vice chairpersons to oversee global strategy, and simultaneously faced a class action antitrust lawsuit regarding component pricing.

Why Revenue Matters for Investors

Revenue provides individual investors with a transparent, direct baseline measurement of all incoming capital over a specific timeframe before any operational business expenses are formally deducted. Closely tracking this top-line financial figure helps investors understand the total scale and growth trajectory of a business.

ASML Holding vs. SK Hynix Revenue chart

Quarterly Revenue for ASML Holding and SK Hynix

Calendar quarterASML Holding RevenueSK Hynix Revenue
Q3 2024$8.2 billion (quarter ended Sept. 30, 2024)$12.9 billion (quarter ended Sept. 30, 2024)
Q4 2024$9.9 billion (quarter ended Dec. 31, 2024)$14.1 billion (quarter ended Dec. 31, 2024)
Q1 2025$8.2 billion (quarter ended March 31, 2025)$12.1 billion (quarter ended March 31, 2025)
Q2 2025$8.7 billion (quarter ended June 30, 2025)$15.8 billion (quarter ended June 30, 2025)
Q3 2025$8.8 billion (quarter ended Sept. 30, 2025)$17.6 billion (quarter ended Sept. 30, 2025)
Q4 2025$11.3 billion (quarter ended Dec. 31, 2025)$22.6 billion (quarter ended Dec. 31, 2025)
Q1 2026$10.3 billion (quarter ended March 31, 2026)$35.7 billion (quarter ended March 31, 2026)
Q2 2026$10.8 billion (quarter ended June 30, 2026)$52.6 billion (quarter ended June 30, 2026)

Data source: Financial Modeling Prep. ASML Holding's figures are converted from euros to U.S. dollars. SK Hynix's figures are converted from South Korean won to U.S. dollars. Data as of Sept. 25, 2026.

Foolish Take

For investors interested in gaining exposure to the artificial intelligence boom, ASML and SK Hynix are two great companies to invest in. Both provide key products to the AI industry, and as a result, are seeing year-over-year revenue growth.

That said, examining their sales trends provides investors with revealing insights. ASML's extreme ultraviolet (EUV) lithography equipment is essential for semiconductor manufacturers to produce AI chips, giving the company a legal monopoly since competitors have not been entirely successful in providing rival EUV tools. However, the complex machinery takes time to build, resulting in a slow revenue ramp for ASML.

In contrast, SK Hynix manufactures high-bandwidth memory (HBM) products, which can be produced faster. The company's massive sales growth in recent quarters is evidence that tech giants are pouring funds into memory components right now. The demand is so great, it's led to rising memory prices, which further fuels SK Hynix's spectacular sales ascent.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a β€œDouble Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $593,741!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $63,526!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $375,240!*

Right now, we’re issuing β€œDouble Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.

See the 3 stocks Β»

*Stock Advisor returns as of October 1, 2026.

Robert Izquierdo has positions in ASML. The Motley Fool has positions in and recommends ASML. The Motley Fool has a disclosure policy.

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Key Points

  • Johnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption.

  • Both companies experienced a gentle pattern of quarter-over-quarter revenue growth over the last two calendar years, though the exact quarterly figures occasionally fluctuated between consecutive reporting periods.

  • Investors should monitor whether the existing revenue gap between the two companies continues to gradually expand or begins to narrow during upcoming quarterly reporting cycles.

Bristol Myers Squibb: Slow and Steady Revenue Growth

Bristol Myers Squibb (NYSE:BMY) operates as a global biopharmaceutical entity that researches, develops, and commercializes a worldwide medicinal portfolio spanning therapeutic areas like hematology, oncology, and cardiovascular health, offering pharmaceutical products such as Revlimid and Eliquis.

It received accelerated regulatory approval from the U.S. Food and Drug Administration for its Zenbexus combination therapy for adult patients with multiple myeloma in August 2026, and it selected Houston for a new $2.3 billion multi-modal manufacturing campus designed to increase its production capacity for next-generation medicines.

Johnson & Johnson: Maintaining a Larger Revenue Base

Johnson & Johnson (NYSE:JNJ) functions as a broad healthcare holding company that engages in the research, development, manufacture, and global sale of products primarily through its dedicated innovative medicine and medical technology segments.

It finalized a $1 billion cash acquisition of Firefly Bio in July 2026 to integrate a targeted antibody-drug conjugate platform, while it also secured regulatory approval for its IMAAVY treatment for patients dealing with warm autoimmune hemolytic anemia.

Why Revenue Matters for Investors

Revenue here refers to the data provider's standardized income-statement revenue line item, which gives investors a direct baseline measurement of the total volume of money a business brings in from its core commercial operations before deducting any associated operating expenses, interest, or taxes.

Bristol-Myers Squibb vs. Johnson & Johnson Revenue chart

Comparing Quarterly Revenue for Bristol Myers Squibb and Johnson & Johnson

Calendar quarterBristol-Myers Squibb RevenueJohnson & Johnson Revenue
Q3 2024$11.9 billion (quarter ended Sept. 30, 2024)$22.5 billion (quarter ended Sept. 29, 2024)
Q4 2024$12.3 billion (quarter ended Dec. 31, 2024)$22.5 billion (quarter ended Dec. 29, 2024)
Q1 2025$11.2 billion (quarter ended March 31, 2025)$21.9 billion (quarter ended March 30, 2025)
Q2 2025$12.3 billion (quarter ended June 30, 2025)$23.7 billion (quarter ended June 29, 2025)
Q3 2025$12.2 billion (quarter ended Sept. 30, 2025)$24.0 billion (quarter ended Sept. 28, 2025)
Q4 2025$12.5 billion (quarter ended Dec. 31, 2025)$24.6 billion (quarter ended Dec. 28, 2025)
Q1 2026$11.5 billion (quarter ended March 31, 2026)$24.1 billion (quarter ended March 29, 2026)
Q2 2026$13.0 billion (quarter ended June 30, 2026)$25.3 billion (quarter ended June 28, 2026)

Data source: Financial Modeling Prep. Data as of Sept. 25, 2026.

Foolish Take

Both Bristol Myers Squibb and Johnson & Johnson are consistently, if slowly, growing their revenue, though Johnson & Johnson is obviously starting from a much larger base. In fact, despite Johnson & Johnson's revenue being about double that of Bristol Myers Squibb, over the period shown above, it grew its revenue at a slightly higher rate. That's impressive.

One thing to watch from here will be Johnson & Johnson's medical technology division, an area Bristol Myers Squibb, a biopharmaceuticals company, doesn't have. J&J's medtech division grew operational sales 3.6% in the second quarter, and in 2025, it generated $33.79 billion in revenue. It's growing the segment via both acquisitions and in-house research and development, which can be costly. However, once those products are approved and in use, they can generate exceptional revenue and high profit margins.

In July, J&J received FDA market authorization in the U.S. for its OTTAVA Robotic Surgical System, "the world's first table-integrated soft tissue robotic system." At the time of the announcement, a U.S. clinical trial for OTTAVA in inguinal hernia procedures was ongoing. Customer uptake and success with this system could provide a strong moat and a new recurring revenue stream for the legacy healthcare company.

Should you buy stock in Bristol Myers Squibb right now?

Before you buy stock in Bristol Myers Squibb, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $375,240!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,403,292!*

Now, it’s worth noting Stock Advisor’s total average return is 932% β€” a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks Β»

*Stock Advisor returns as of October 1, 2026.

Sarah Sidlow has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

❌